Outpatient transfusions for myelodysplastic syndromes | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Outpatient transfusions for myelodysplastic syndromes

Journal Title: 
Hematology. American Society of Hematology. Education Program
Primary Author: 
Wood EM
Erica M Wood, Zoe K McQuilten
Original Publication Date: 
Friday, December 4, 2020
Bone Marrow Disease(s): 

Patients with myelodysplastic syndromes (MDS) often need extended periods of red blood cell or platelet transfusion support, with the goal to manage symptoms of anemia and thrombocytopenia, respectively, and improve quality of life. Many questions about the optimal approach to transfusion management in MDS, especially in the outpatient setting, remain unanswered, including hemoglobin and platelet thresholds for transfusion. Restrictive transfusion approaches are often practised, but whether these are appropriate for outpatients with MDS, who are often older and may be frail, is not known. Current schedules for transfusion-dependent patients are burdensome, necessitating frequent visits to hospitals for sample collection and blood administration. Questions of optimal schedule and dosage are being explored in clinical trials, including the recently completed REDDS study. Patient-reported outcomes and functional assessments are increasingly being incorporated into research in this area so that we can better understand and improve transfusion support for patients with MDS.